A $2,500 investment in a dividend knight and safe-haven stock can create a balanced foundation to counter market headwinds in ...

Build a free 2026 Excel budget file with bank import and XLOOKUP categories, so you track spending and savings without manual typing.

As Eli Lilly (NYSE: LLY) and Novo Nordisk (Nasdaq Copenhagen: NOVO-B) scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, a much smaller potential rival ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

MANILA, Philippines (AP) — World shares rose on Friday, tracking Wall Street’s climb to records despite a sell-off for Oracle as worries persisted about a potential bubble in artificial-intelligence ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. 10 stocks we like better than Structure Therapeutics › Monday ...

Shares of Intel surged in September after a big investment from chipmaker Nvidia. In addition, the Trump administration has taken a 10% stake in the business. Intel, however, has incurred an operating ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...

Shares of Structure Therapeutics Inc. (NASDAQ: GPCR) are soaring Monday after the clinical-stage biopharmaceutical company reported positive topline data from a weight loss drug trial. The positive ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The South San Francisco biotech ...

It was a pretty straightforward overnight session with a very high degree of correlation between bond yields and stock prices. The final leg of the rally arrived on comments from NY Fed Pres Williams ...